A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

NCT07414953 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: HS-10504
DRUG: SHR-A2009
DRUG: HS-20122
DRUG: HS-20117
DRUG: SHR-1826
DRUG: SHR-A2102

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.